540737-29-9 C16H20N6O.C6H8O7 Tofacitinib citrate
Min.Order / FOB Price:Get Latest Price
| 1 Kilogram |
Negotiable |
- Min.Order :1 Kilogram
- Purity: 99%
- Payment Terms : L/C,D/A,D/P,T/T,
Keywords
BETA-OXO 3-propanetricarboxylate 1-Piperidinepropanenitrile
Quick Details
- Appearance:As detailed
- Application:540737-29-9
- PackAge:As required
- ProductionCapacity:100-200|Kilogram|Month
- Storage:room temperatuure
- Transportation:By air/sea/express
Superiority:
About Certificate
1.Certificate Of Analysis (COA)
2.Material Safety Data Sheet (MSDS)
3.Route of synthesis (ROS)
4.Method of Aanlysis(MOA)
5.Nuclear Magnetic Resonance(NMR)
About Service
1. Quality control, before shipment, free sample for test.
2. Prompt shipment with professional documents
3. Packing as your request, with photo before shipment
4. Mixed containers with different mixed items in one container
About Company
HenNan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.
We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
Details:
| Product Name: | Tofacitinib citrate |
| Synonyms: | 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s...;Xeljanz;CP-690550 (Tofacitinib citrate) |
| CAS: | 540737-29-9 |
| MF: | C16H20N6O.C6H8O7 |
| MW: | 504.497 |
| EINECS: | |
| Product Categories: | Inhibitor;Inhibitors |
| Mol File: | 540737-29-9.mol |
|
|
|
| Tofacitinib citrate Chemical Properties |
| storage temp. | room temp |
| Safety Information |
| Tofacitinib citrate Usage And Synthesis |
| Drug forTreatment of rheumatoid arthritis |
Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis , trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily. November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients. Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Xeljanz is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function. In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis. Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks . Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values. In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control. The above information is edited by the Chemicalbook of Tian Ye. |
| Application |
Jak kinase inhibitor, to treat rheumatoid arthritis. Tropsch erlotinib (477600-75-2) bulk pharmaceutical chemicals. |
| Tofacitinib citrate Preparation Products And Raw materials |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View